The Manufacturers Life Insurance Company Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

The Manufacturers Life Insurance Company acquired a new position in Capricor Therapeutics Inc (NASDAQ:CAPR) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 10,558 shares of the biotechnology company’s stock, valued at approximately $161,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CAPR. Renaissance Technologies LLC lifted its position in shares of Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares during the period. Marshall Wace LLP bought a new position in Capricor Therapeutics in the second quarter worth approximately $426,000. Bank of New York Mellon Corp lifted its holdings in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares during the period. Oppenheimer & Co. Inc. boosted its position in Capricor Therapeutics by 25.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock valued at $1,040,000 after acquiring an additional 13,762 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics in the 2nd quarter valued at $147,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Stock Up 4.7 %

CAPR stock opened at $13.88 on Tuesday. The stock has a market capitalization of $631.12 million, a PE ratio of -13.09 and a beta of 3.98. Capricor Therapeutics Inc has a 52 week low of $3.52 and a 52 week high of $23.40. The firm has a 50 day moving average of $18.33 and a 200 day moving average of $10.13.

Insiders Place Their Bets

In other news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the company’s stock in a transaction on Friday, September 20th. The shares were acquired at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the purchase, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. This trade represents a 65.21 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 12.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on CAPR shares. Oppenheimer restated an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. HC Wainwright reissued a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald lifted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Finally, Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price for the company. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.